Cost Effectiveness Standard: Drugs Should Be “Innocent Until Proven Guilty”
Executive Summary
Policies governing evidence-based medicine should presume that new drugs or devices are cost effective until comparative studies prove otherwise, AstraZeneca Director-Strategic Planning & Business Development Kim Slocum said during an April 27 1"Drug & Device Dialogue" audio conference sponsored by F-D-C Reports and Polidais